Loading clinical trials...
Loading clinical trials...
A Phase 1, Open Label, Randomized Study to Investigate the Pharmacokinetics and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adult Participants
Conditions
Interventions
16 mg naloxone AP003
8 mg naloxone NARCAN Nasal Spray
Locations
1
United States
Syneos Health Clinical Research Services
Miami, Florida, United States
Start Date
March 28, 2022
Primary Completion Date
May 10, 2022
Completion Date
May 10, 2022
Last Updated
April 15, 2026
NCT06527079
NCT04372238
NCT05114460
NCT05876572
NCT05096429
NCT06005402
Lead Sponsor
Emergent BioSolutions
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions